Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000
Debt
Debt-to-Equity Ratio0.32
Current Ratio7.07
Quick Ratio7.07
Price-To-Earnings
Trailing P/E Ratio-3.22
Forward P/E Ratio-4.20
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.37 million
Price / Sales33.85
Cash FlowN/A
Price / CashN/A
Book Value$2.04 per share
Price / Book4.09
Profitability
EPS (Most Recent Fiscal Year)($2.59)
Net Income$-127,790,000.00
Net Margins-172.27%
Return on Equity-99.50%
Return on Assets-42.59%
Miscellaneous
Employees137
Outstanding Shares54,200,000
Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions
What is Cytokinetics' stock symbol?
Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."
How were Cytokinetics' earnings last quarter?
Cytokinetics (NASDAQ:CYTK) released its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company had revenue of $5.27 million for the quarter, compared to analyst estimates of $5.50 million. Cytokinetics had a negative return on equity of 99.50% and a negative net margin of 172.27%. View Cytokinetics' Earnings History.
When is Cytokinetics' next earnings date?
What price target have analysts set for CYTK?
8 brokerages have issued 1 year target prices for Cytokinetics' stock. Their forecasts range from $10.00 to $24.00. On average, they anticipate Cytokinetics' stock price to reach $15.6250 in the next twelve months. View Analyst Ratings for Cytokinetics.
What are Wall Street analysts saying about Cytokinetics stock?
Here are some recent quotes from research analysts about Cytokinetics stock:
- 1. Cantor Fitzgerald analysts commented, "Reldesemtiv and omecamtiv mecarbil, CYTK’s lead programs, have sizable opportunities given the limited treatment options in the markets that are being explored but are novel mechanisms, which enhances the risk profile, in our view. The loss of tirasemtiv was a sizable blow to CYTK and new data for reldesemtiv are a plus, in our view, with the shares now essentially at our price target." (6/17/2018)
- 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
- 3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)
Who are some of Cytokinetics' key competitors?
Some companies that are related to Cytokinetics include Akcea Therapeutics (AKCA), Spectrum Pharmaceuticals (SPPI), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Insmed (INSM), Endo International (ENDP), ACADIA Pharmaceuticals (ACAD), Prestige Brands (PBH), Akorn (AKRX), Phibro Animal Health (PAHC), Aimmune Therapeutics (AIMT), AnaptysBio (ANAB), PTC Therapeutics (PTCT), Myokardia (MYOK) and Mallinckrodt (MNK).
Who are Cytokinetics' key executives?
Cytokinetics' management team includes the folowing people:
- Mr. Robert I. Blum, CEO, Pres & Director (Age 54)
- Mr. Ching W. Jaw, Sr. VP & CFO (Age 55)
- Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 63)
- Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 54)
- Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 58)
Has Cytokinetics been receiving favorable news coverage?
News stories about CYTK stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cytokinetics earned a coverage optimism score of 0.11 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 43.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Cytokinetics' major shareholders?
Cytokinetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.44%), Wasatch Advisors Inc. (3.26%), Pinnacle Associates Ltd. (1.64%), Citigroup Inc. (1.43%), Principal Financial Group Inc. (0.73%) and Principal Financial Group Inc. (0.74%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.
Which major investors are selling Cytokinetics stock?
CYTK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc. and American International Group Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics.
Which major investors are buying Cytokinetics stock?
CYTK stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Millennium Management LLC, Employees Retirement System of Texas, A.R.T. Advisors LLC, UBS Group AG, JPMorgan Chase & Co., BlackRock Inc. and DRW Securities LLC. View Insider Buying and Selling for Cytokinetics.
How do I buy shares of Cytokinetics?
Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytokinetics' stock price today?
One share of CYTK stock can currently be purchased for approximately $8.35.
How big of a company is Cytokinetics?
Cytokinetics has a market capitalization of $536.56 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.
How can I contact Cytokinetics?
Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]
MarketBeat Community Rating for Cytokinetics (CYTK)
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
